Monastrol

CAS No. 254753-54-3

Monastrol( Monastrol )

Catalog No. M19323 CAS No. 254753-54-3

Monastrol is a potent and cell-permeable inhibitor of the mitotic kinesin Eg5.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Monastrol
  • Note
    Research use only, not for human use.
  • Brief Description
    Monastrol is a potent and cell-permeable inhibitor of the mitotic kinesin Eg5.
  • Description
    Monastrol is a kinesin Eg5 inhibitor. Induction of apoptosis by monastrol is independent of the spindle checkpoint. Monastrol binds to the KSP-ADP complex, forming a KSP-ADP- monastrol ternary complex, which cannot bind to microtubules productively and cannot undergo further ATP-driven conformational changes.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Monastrol
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    Eg5
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    254753-54-3
  • Formula Weight
    292.35
  • Molecular Formula
    C14H16N2O3S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCOC(=O)C1=C(NC(=S)NC1C2=CC(=CC=C2)O)C
  • Chemical Name
    ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Cochran JC, et al. Monastrol inhibition of the mitotic kinesin Eg5. J BiolChem. 2005 Apr 1;280(13):12658-67.
molnova catalog
related products
  • Panitumumab

    Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).

  • VUF 10166

    VUF10166 is a novel, potent and competitive antagonist for 5-HT3A receptor with Ki of 0.04 nM, its affinity at 5-HT3AB receptor is significantly lower.

  • Epimedin B

    Epimedin B has potential activity against osteoporosis by stimulating osteoblasts.